• 10.09.2019 – 09:40

  Grünenthal Group

  Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain

  Aachen, Germany, and Melbourne, Australia (ots) - Grünenthal, a global leader in pain management, and Mesoblast Limited (ASX: MSB; Nasdaq: MESO), a world leader in allogeneic cellular medicines for inflammatory diseases, today announced that they have entered into a strategic partnership to develop and ...

• 02.05.2019 – 14:00

  Grünenthal Group

  Five young scientists win EFIC-Grünenthal Grant 2018

  Brussels/Aachen (ots) - - Five creative ideas aimed at advancing research in pain have been selected to receive funding from the prestigious EFIC-Grünenthal Grant (E-G-G) 2018. - The selected teams of young scientists will start executing there innovative projects with the ambitious objective to improve the lives of people in pain. The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have ...

• 05.11.2018 – 12:10

  Grünenthal Group

  Grünenthal acquires global rights for Qutenza®

  Aachen (ots) - Grünenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza® (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grünenthal is now the sole owner of Qutenza® worldwide, including the US, Latin America, Asia and Australia. Grünenthal had already acquired exclusive commercial rights for ...

• 30.10.2018 – 08:43

  Grünenthal Group

  Grünenthal agrees US$ 922 m deal with AstraZeneca for Nexium and Vimovo

  Aachen (ots) - - Biggest single investment in Grünenthal's history that will significantly strengthen the company's leading position in pain management - Gastroprotective therapies to address a high unmet medical need [1] in pain patients on non-steroidal anti-inflammatory drugs (NSAIDs) Grünenthal today announced that it has agreed to acquire AstraZeneca's European ...